concept

CRY

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about CRY: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

131Connections

2Hypotheses

0Analyses

50Outgoing

44Incoming

10Experiments

Summary

CRY is a concept in neurodegeneration research. Key relationships include: regulates, expressed in, activates. Associated with ALS, Als, Alzheimer. Connected to 84 entities in the SciDEX knowledge graph.

View on Wiki →

💡 Concept Info

Name	CRY
Key Genes/Proteins	CLOCK-BMAL1, PER
Related Diseases	Glioblastoma Growth, Insomnia, Inflammation, Als
Related Pathways	circadian rhythm, Metabolism
Linked Hypotheses	2 hypotheses

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    CRY["CRY"]
    CRY -->|"inhibits"| CLOCK_BMAL1["CLOCK-BMAL1"]
    CRY -->|"involved_in"| Circadian_Rhythms["Circadian Rhythms"]
    CRY -->|"regulates"| Cellular_Metabolism["Cellular Metabolism"]
    CRY -->|"regulates"| Inflammation["Inflammation"]
    CRY -->|"regulates"| Als["Als"]
    CRY -->|"regulates"| Neuroinflammation["Neuroinflammation"]
    CRY -->|"regulates"| Alzheimer["Alzheimer"]
    CRY -->|"regulates"| Parkinson["Parkinson"]
    CRY -->|"regulates"| Obesity["Obesity"]
    CRY -->|"regulates"| Ms["Ms"]
    PER["PER"] -->|"interacts"| CRY
    GENES["GENES"] -->|"expressed in"| CRY
    ARNT["ARNT"] -->|"expressed in"| CRY
    BMAL1["BMAL1"] -->|"expressed in"| CRY
    CLOCK["CLOCK"] -->|"expressed in"| CRY
    CAMK2A["CAMK2A"] -->|"expressed in"| CRY

Outgoing (87)

Target	Relation	Type	Str
METABOLIC HEALTH	regulates	entity	0.95
circadian rhythm	drives	process	0.95
CLOCK-BMAL1	inhibits	protein	0.90
Circadian Rhythms	involved_in	process	0.90
Cellular Metabolism	regulates	process	0.90
Glioblastoma Growth	regulates	phenotype	0.90
Circadian Gene Expression	involved_in	process	0.90
Circadian Rhythm Regulation	regulates	process	0.90
LIPID METABOLISM	regulates	entity	0.85
Insomnia	associated_with	disease	0.80
circadian rhythm	participates_in	biological_process	0.80
Metabolism	regulates	biological_process	0.80
Inflammation	regulates	disease	0.65
Als	regulates	disease	0.65
Neuroinflammation	regulates	disease	0.65
Alzheimer	regulates	disease	0.65
Parkinson	regulates	disease	0.65
Obesity	regulates	disease	0.65
Ms	regulates	disease	0.65
Diabetes	regulates	disease	0.65
Cancer	expressed_in	disease	0.65
Cardiovascular	expressed_in	disease	0.65
Metabolic Syndrome	expressed_in	disease	0.65
Obesity	expressed_in	disease	0.65
Ms	expressed_in	disease	0.65
Diabetes	expressed_in	disease	0.65
Cancer	activates	disease	0.65
Glioblastoma	activates	disease	0.65
Als	activates	disease	0.65
Tumor	activates	disease	0.65
Ms	activates	disease	0.65
Cancer	associated_with	disease	0.65
Cardiovascular	associated_with	disease	0.65
Diabetes	associated_with	disease	0.65
Metabolic Syndrome	associated_with	disease	0.65
Obesity	associated_with	disease	0.65
Depression	expressed_in	disease	0.65
ALS	regulates	disease	0.65
ALS	activates	disease	0.65
Metabolic Syndrome	interacts_with	disease	0.65
Cancer	interacts_with	disease	0.65
circadian regulation	participates_in	pathway	0.65
BMAL1	associated_with	gene	0.60
CLOCK	associated_with	gene	0.60
Oxidative Stress	regulates	pathway	0.60
Lipid Metabolism	regulates	pathway	0.60
Circadian Rhythm	regulates	pathway	0.60
Sleep-Wake	regulates	pathway	0.60
BMAL1	expressed_in	gene	0.60
CLOCK	expressed_in	gene	0.60

Incoming (44)

Source	Relation	Type	Str
PER	interacts_with	gene	0.80
BMAL1	associated_with	gene	0.60
GENES	associated_with	gene	0.60
GENES	expressed_in	gene	0.60
GENES	activates	gene	0.60
CLOCK	associated_with	gene	0.60
ARNT	expressed_in	gene	0.60
BMAL1	expressed_in	gene	0.60
CLOCK	expressed_in	gene	0.60
BMAL1	activates	gene	0.60
CLOCK	activates	gene	0.60
PER	inhibits	gene	0.60
CAMK2A	expressed_in	gene	0.60
ALZHEIMER	regulates	gene	0.60
NEURODEGENERATIVE DISORDERS	regulates	gene	0.60
NEURODEGENERATIVE DISEASES	regulates	gene	0.60
PER	associated_with	gene	0.60
PARKINSON	regulates	gene	0.60
PER	expressed_in	gene	0.60
GLIOBLASTOMA	activates	gene	0.60
GBM	activates	gene	0.60
AND	activates	gene	0.60
PER	activates	gene	0.60
CIRCADIAN OUTPUT GENES	expressed_in	gene	0.60
AND	expressed_in	gene	0.60
CANCER	expressed_in	gene	0.60
CLOCK GENE	expressed_in	gene	0.60
BMAL1	interacts_with	gene	0.60
CLOCK	interacts_with	gene	0.60
CRY1	inhibits	gene	0.60
CANCER	interacts_with	gene	0.60
DNA	interacts_with	gene	0.60
AND	interacts_with	gene	0.60
REST	interacts_with	gene	0.60
GENES	regulates	gene	0.60
OXIDATIVE STRESS	regulates	gene	0.60
NEUROINFLAMMATION	regulates	gene	0.60
AND	associated_with	gene	0.60
CANCER	activates	gene	0.60
CLOCK GENES	activates	gene	0.60
ARNT	regulates	gene	0.60
BMAL1	regulates	gene	0.60
CLOCK	regulates	gene	0.60
AMPK	causes	gene	0.60

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TDP-43 Cryptic Exon–Targeted ASOs to Restore Hippocampal Gam	0.577	neurodegeneration	RNA binding protein dysregulation across
Cryptic Exon Silencing Restoration	0.462	neurodegeneration	RNA binding protein dysregulation across

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (10)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD	validation	ALS	0.400	0.50	human	proposed	$2,730,000
FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000
Pre-Symptomatic Detection and Intervention Timing in Genetic Prion Dis	validation	ALS	0.400	0.50	human	proposed	$2,280,000
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD	validation	ALS	0.400	0.50	human	proposed	$2,730,000
Environmental Exposure Causal Attribution in ALS — Experiment Design	validation	ALS	0.400	0.50	human	proposed	$3,000,000
Progranulin Replacement Therapy for FTD — Vector Development and Valid	clinical	ALS	0.400	0.50	human	proposed	$5,460,000
ALS Progression Rate Heterogeneity — mechanism and biomarker predictor	clinical	ALS	0.400	0.50	human	proposed	$6,550,000
TDP-43 PET Ligand Development for FTD and ALS	clinical	ALS	0.400	0.50	human	proposed	$6,550,000
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutation Carriers	validation	ALS	0.400	0.50	human	proposed	$3,000,000
Frontal and Temporal Lobe Selective Vulnerability in FTD — Mechanisms	validation	Neurodegeneration	0.400	0.50	human	proposed	$3,000,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Targets and Gene Therapy of ALS (Part 1). [PMID:40362304]	Shiryaeva O, Tolochko C, Alekseeva T, Dy	Int J Mol Sci	2025	1
The genetics of amyotrophic lateral sclerosis. [PMID:38967083]	Nijs M, Van Damme P	Curr Opin Neurol	2024	1
TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhi [PMID:39305312]	Torres P, Rico-Rios S, Ceron-Codorniu M,	Acta Neuropathol	2024	1
TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. [PMID:35197628]	Brown AL, Wilkins OG, Keuss MJ, Kargbo-H	Nature	2022	1
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP- [PMID:28405022]	Becker LA, Huang B, Bieri G, Ma R, Knowl	Nature	2017	1
Selective Silencing of TDP-43 P. G376D Mutation Reverses Key Amyotrophic Lateral [PMID:41897327]	Romano R, Ruotolo G, Perrone F, Tomasell	Biomolecules	2026	0
ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies. [PMID:41570741]	Genin EC, Paquis-Flucklinger V	Current opinion in neurobiolog	2026	0
Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Protein [PMID:41900026]	Jamerlan A, Hulme J	Molecules (Basel, Switzerland)	2026	0
Axonal transport impairment as an upstream mechanism in amyotrophic lateral scle [PMID:41890591]	Gabbay U	Frontiers in neuroscience	2026	0
Role of Alpha-Synuclein in Frontotemporal Dementia: Narrative Review. [PMID:41827903]	Bougea A	Cells	2026	0
Versatile CRISPR-Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Bi [PMID:41671402]	["Shi M", "Ge W", "Li C", "Liu B", "Deng	Advanced science (Weinheim, Ba	2026	0
Splicing the narrative: alternative TARDBP splicing and its relation to neurodeg [PMID:41837283]	Miller MR, Dykstra M, Barmada S	The Journal of clinical invest	2026	0
Multi-modal dissection of cell-type specific TDP-43 pathology in the motor corte [PMID:41803120]	Ruf WP, Kühlwein JK, Meier L, Brockmann	Nature communications	2026	0
A neurotoxic cryptic peptide arising from TDP-43-dependent cryptic splicing of P [PMID:41720774]	["Yang M", "Wang Q", "Yan R", "Kang D",	Nature communications	2026	0
The Genetics of TDP-43 Type C Neurodegeneration: A Whole-Genome Sequencing Study [PMID:41883703]	Nassan M, Ayala I, Sloan J, Bonfitto A,	Neurology. Genetics	2026	0
Excitotoxicity in amyotrophic lateral sclerosis: a key pathogenic mechanism. [PMID:41890274]	Silva-Hucha S, Hernández RG, Baena-López	Brain communications	2026	0
PPAR-Delta Agonist Therapies Did Not Rescue Hallmark Disease Phenotypes in Two S [PMID:41751955]	["Luong D", "Niu C", "Kim E", "Tanji N",	International journal of molec	2026	0
Transcriptomic signature of frontotemporal lobar degeneration with TDP-43 type C [PMID:41789476]	["Rajicic A", "Mol M", "Melhem S", "Kisi	Brain : a journal of neurology	2026	0
Antisense oligonucleotide targeting TARDBP-EGFR splicing axis inhibits progressi [PMID:41540015]	Ni N, Wang M, Yuan Z, Zhang L, Cai J, Du	International journal of oral	2026	0
TDP-43 impairs glycolysis by sequestering hexokinase 1 in amyotrophic lateral sc [PMID:41838122]	Barone C, Wang R, Cooke S, Ng HP, Ferrei	Acta neuropathologica	2026	0

CRY

Understanding Entity Pages

Summary

Wiki Pages (20)

Microglial Cells — Cell Type Hierarchy

Circadian Rhythm in Neurodegeneration

Circadian Rhythm Modulation Therapy

Type 3 Diabetes Hypothesis of Alzheimer's Disease

Sleep-Wake Cycle

Circadian Dysfunction Across Neurodegenerative Diseases

Circadian Rhythm Dysfunction in Alzheimer's Disease

sleep-disruption-neurodegeneration

Circadian Disruption in Neurodegeneration

Circadian Rhythm Disruption in Neurodegeneration

rgs16

Hypothalamic-Pituitary-Adrenal Axis

Alpers-Huttenlocher Syndrome

atxn3-protein

Circadian Rhythm Dysfunction in Corticobasal Syndrome

RBM25 Protein

Hypothalamus

FBXO7 Protein (PARK15)

Binswanger Disease